KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to -$4.9 million.

  • Rigel Pharmaceuticals' Net Cash Flow fell 13115.93% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 14939.47%. This contributed to the annual value of $24.0 million for FY2024, which is 18773.87% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Net Cash Flow stood at -$4.9 million, which was down 13115.93% from $7.7 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Net Cash Flow's 5-year high stood at $64.8 million during Q2 2021, with a 5-year trough of -$54.4 million in Q3 2021.
  • In the last 5 years, Rigel Pharmaceuticals' Net Cash Flow had a median value of $2.5 million in 2022 and averaged $958842.1.
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' Net Cash Flow was 83978.99% (2021), while the steepest drop was 5563061.22% (2021).
  • Over the past 5 years, Rigel Pharmaceuticals' Net Cash Flow (Quarter) stood at -$11.5 million in 2021, then surged by 53.04% to -$5.4 million in 2022, then plummeted by 133.55% to -$12.6 million in 2023, then soared by 140.02% to $5.1 million in 2024, then crashed by 196.42% to -$4.9 million in 2025.
  • Its last three reported values are -$4.9 million in Q3 2025, $7.7 million for Q2 2025, and -$11.0 million during Q1 2025.